Showing 1221-1230 of 1414 results for "".
- Adaptive Biotechnologies and Microsoft Expand Partnership to Decode COVID-19 Immune Response and Provide Open Data Accesshttps://modernod.com/news/adaptive-biotechnologies-and-microsoft-expand-partnership-to-decode-covid-19-immune-response-and-provide-open-data-access/2477435/Adaptive Biotechnologies and Microsoft announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19. Finding the relevant immune response signature may advance solutions to diagnose, treat and prevent the disease,
- Allergan, Sightsavers, and the IAPB Announce the “Keep Sight” Initiative to Address Glaucoma in Ganjam, Odishahttps://modernod.com/news/allergan-sightsavers-and-the-iapb-announce-the-keep-sight-initiative-to-address-glaucoma-in-ganjam-odisha/2477318/Allergan, Sightsavers, and the International Agency for the Prevention of Blindness (IAPB) announced the launch of its unique joint initiative, ‘Keep Sight India,’ a community-based glaucoma screening program to prevent glaucoma-related vision loss in Ganjam District, Odisha. The pilot kicked off
- MacuLogix Introduces the AdaptDx Pro Guided by Theiahttps://modernod.com/news/maculogix-introduces-the-adaptdx-pro-guided-by-theia/2477230/MacuLogix has introduced the AdaptDx Pro guided by Thei, a next generation dark adaptation functional testing. The company’s original AdaptDx automated dark adaptometer was introduced in 2014 and has since been used by more than 1,000 eye care professionals to identify and monitor AMD. The
- Aldeyra Therapeutics Announces Topline Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-part-1-of-adaptive-phase-3-renew-trial-in-dry-eye-disease/2477138/Aldeyra Therapeutics announced positive topline results from Part 1 of the adaptive phase 3 RENEW trial of topical ocular reproxalap in patients with dry eye disease, according to a company news release. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate
- AbbVie’s Humira (Adalimumab) Approved by Health Canada to Treat Pediatric Patients with Chronic Noninfectious Anterior Uveitishttps://modernod.com/news/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-noninfectious-anterior-uveitis/2476279/AbbVie announced that Health Canada has approved Humira (adalimumab) for the treatment of chronic noninfectious anterior uveitis in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropr
- MacuLogix Launches the AdaptDx in Europehttps://modernod.com/news/maculogix-launches-the-adaptdx-in-europe-at-euretina/2479856/MacuLogix will launch the AdaptDx in Europe during its debut at the European Society of Retina Specialists (EURETINA) annual congress
- Dark Adaptation Testing with AdaptDx Selected for Functional Assessment in Large EU Studyhttps://modernod.com/news/dark-adaptation-testing-with-adaptdx-selected-for-functional-assessment-in-large-eu-study/2480239/MacuLogix announced that the AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for f
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Study Compares Nanodropper Adaptor Versus Conventional Eye Drops for Glaucomahttps://modernod.com/news/study-compares-nanodropper-adaptor-versus-conventional-eye-drops-for-glaucoma/2482176/Nanodropper announced the publication of a company-sponsored study<
- Nicox Presents NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis at the World Glaucoma Congresshttps://modernod.com/news/nicox-presents-ncx-470-phase-3-mont-blanc-adaptive-design-data-and-additional-subset-analysis-at-the-world-glaucoma-congress/2481705/Nicox presented additional data on NCX 470 at the 10th World Glaucoma Congress (WGC) in Rome, Italy. “The large volume of data generated in the Mont Blanc phase 3 trial on NCX 470 has provided us with the opportunity to look in detail at patient subgroups to further